Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]

Expanding clinical trial eligibility criteria: Risks and solutions

Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA

Expanding clinical trial eligibility criteria: Risks and solutions ( Dr Jorge Nieva - Keck School of Medicine of USC, Los Angeles, USA )

Ribociclib plus endocrine therapy improves survival in premenopausal patients...

Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston...

Ribociclib plus endocrine therapy improves survival in premenopausal patients with metastatic breast cancer ( Prof Debu Tripathy - The University of Texas MD Anderson Cancer Center, Houston, USA )

ASCO 2019 and vision for cancer control

Dr Eduardo Cazap - Editor-in-Chief, ecancer

ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland...

Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA

Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial ( Prof Bob Li - Memorial Sloan Kettering Cancer Center, New York City, USA )

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2...

Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA

Mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2 mutated metastatic breast cancer ( Dr Adrienne Waks - Dana-Farber Cancer Institute, Boston, USA )

Guiding treatment decisions through the use of molecular profiling in breast...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Managing metastatic breast cancer and beyond using PARP inhibitors

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Updates in metastatic and early-stage breast cancer

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor...

Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands

Modular phase I/II clinical trial evaluating the selective MET-kinase inhibitor OMO-1 in patients with advanced malignancies ( Dr Martijn Lolkema - Erasmus University Medical Center, Rotterdam, Netherlands )

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG...

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany

VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )

More from ecancer